Joshua Rademacher serves as The Oncology Institute of Hope and Innovation’s Chief Development Officer.
Prior to joining The Oncology Institute, Josh was the CEO of Optum’s 503B | 503A operations and served as the Executive Vice President of Corporate Development and Strategy for Avella SRx, the largest independent specialty pharmacy in the US.
Earlier in his career, Josh was the Chief of Staff and head of Strategic Initiatives for the specialty solutions division of Oncology Therapeutics Network and held transactional roles at Madison Capital Funding and Lazard Middle Market.
Joshua holds a B.S. in Economics from Marquette University and an MBA from the University of Chicago.